呼吸内科是以肺部疾病的鉴别诊断、肺癌多学科综合治疗为特色的集医、教、研为一体的学术型科室。科室拥有床位172张，临床医师40名，设有呼吸内镜室，肺功能室，日间化疗病房，普肺及呼吸介入亚学科。年入院患者超过28000例,门诊量逾20万。
呼吸内科是上海交通大学重点学科、卫生部呼吸内镜培训基地、卫生部专科医生培训基地。共有博导4人，硕导10人，主任、副主任医师21人；博士20余人，82%具有研究生以上学历；
科室近5年课题资助40余项，其中国家级数10项。承担科技部重大专项“国产电磁导航系统的早期肺癌精准诊疗技术研究”、上海市卫生系统联合攻关项目“早期肺癌社区筛查”等重大课题。发表论文综述300多篇，获中华医学科技进步二等奖、上海市医学科技进步二等奖；开展药物临床试验50余项，是2018国家I类上市抗癌药物安罗替尼研究的主要组长承担单位，研究成果发表在JAMA Oncology,积极参与并设计了数十项国际合作中国的抗癌新药临床试验，其中参与IPASS研究成果发表在New England Journal of Medicine。与美国耶鲁大学肺癌中心合作，中捷合作成立肺癌免疫治疗示范中心。连续7年成功举办“国际肺癌诊治和呼吸内镜大会”。
Pulmonary Medicine Department
The pulmonary medicine department specializes in the lung disease diagnosis and multi-disciplinary treatment of lung cancer. There are 172 beds and 40 physicians belong to the department, with established endoscope room, lung function laboratory and intervention pulmonology, day chemotherapy ward, general lung and respiratory intervention subdisciplines. More than 28,000 patients were admitted and more than 200,000 outpatients were visited. The quantity of outpatient and inpatient patients is more than 28,000 and 200,000 respectively.
The department is the key discipline listed in Shanghai Jiao Tong University, national teaching base of intervention diagnosis and treatment of Ministry of Health, and national specialist training base of Ministry of Health. There are four tutors of doctoral degree candidates, 10 tutors of postgraduate degree candidates, 21 chief physicians and more than 20 physicians with doctor degree. More than 82 percent of the staff are with postgraduate degree. The department has established cooperation with the Czech Republic and Yale University. The annual conference, international conferences on the diagnosis and treatment of respiratory endoscopy, have been held seven times successfully.
The department was supported by more than 40 funding in the recent five years with 10 national funding. Currently, the department is undertaking national special program, “Early Diagnosis and Treatment Based on Domestic Electromagnetic Navigation System.” More than 300 papers have been published and 50 different clinical trials have been performed.
As a leading PI of Class I Anti-cancer Drug Anlotinib phase 3 Research in 2018, the study results were published on JAMA Oncology. Moreover, the department has been actively participated in and designed dozens of international cooperative clinical trials of new anticancer drugs in China, among IPASS research which were published on New England Journal of Medicine.
It has good collaboration with Yale University Lung Cancer Center in the past 10 years. A Lung Cancer Immunotherapy Demonstration Center has been established between China and Czechoslovakia. The international conference on diagnosis and treatment of lung cancer has been successfully held for consecutive seven years.
